Fuyuan Pharmaceutical announced that it has received a drug registration certificate from the National Medical Products Administration for bromocriptine mesylate tablets, with a specification of 2.5 mg, classified as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. The drug was developed by Novartis, approved for marketing in the United States in 1978 and in China in 1995, and is indicated for endocrine system and nervous system conditions. The company's application was accepted in October 2024 and recently approved, with cumulative research and development investment of approximately 8.4 million yuan.
Beijing Winsunny Pharmaceutical CO.LTDObtained drug registration certificate for bromocriptine mesylate tablets, a new product approval.
